+

WO1997033616A1 - Methodes de traitement de maladies allergiques a l'aide d'ige - Google Patents

Methodes de traitement de maladies allergiques a l'aide d'ige Download PDF

Info

Publication number
WO1997033616A1
WO1997033616A1 PCT/US1997/003443 US9703443W WO9733616A1 WO 1997033616 A1 WO1997033616 A1 WO 1997033616A1 US 9703443 W US9703443 W US 9703443W WO 9733616 A1 WO9733616 A1 WO 9733616A1
Authority
WO
WIPO (PCT)
Prior art keywords
ige
patient
serum
antagonist
week
Prior art date
Application number
PCT/US1997/003443
Other languages
English (en)
Inventor
Donald W. Macglashan, Jr.
Daniel C. Adelman
James D. Reimann
Original Assignee
Genentech, Inc.
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., Johns Hopkins University filed Critical Genentech, Inc.
Priority to AU19875/97A priority Critical patent/AU726143B2/en
Priority to JP53267597A priority patent/JP2001505181A/ja
Priority to IL12611397A priority patent/IL126113A0/xx
Priority to EP97908025A priority patent/EP0904108A1/fr
Publication of WO1997033616A1 publication Critical patent/WO1997033616A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • IgE plays a central role in the cascade of events leading to the early and late airway responses to allergen exposure in allergic asthma.
  • the interaction of allergen with mast cell bound IgE triggers aggregation and crossl inking of IgE receptors, in turn provoking mast cell degranulation with the release of preformed mediators, such as histamine and tryptase, and the synthesis and release of prostaglandins, leukotrienes, and cytokines.
  • mediators such as histamine and tryptase
  • prostaglandins such as histamine and tryptase
  • leukotrienes cytokines
  • IgE antagonist refers to a substance which inhibits the biological activity of IgE Such antagonists include but are not limited to anti-IgE antibodies, IgE receptors anti-IgE receptor antibodies, variants of IgE antibodies, ligands for the IgE receptors, and fragments thereof Antibody antagonists may be of the IgA, IgD, IgG, or IgM class Variant IgE antibodies typically have amino acid substitutions or deletions at one or more am o acid residues
  • Ligands for IgE receptors include but are not limited to IgE and anti-receptor antibodies, and fragments thereof capable of binding to the receptors including amino acid substitution and deletion variants, and cyc zed variants
  • the maintenance dose averages about 0.00075 to 0.0024 mg/kg/week, or about 0.00125 to 0.0024 mg/kg/week, or about 0.00175 to 0.0024 mg/kg/week, of IgE antagonist for every IU/ml baseline free IgE in the patient's serum.
  • the maintenance dose is at least about three fold lower, or at least about six fold lower, or at least about 12 fold lower, or at least about 25 fold lower, or at least about 50 fold lower, than the loading dose in units of mg/kg/week for every IU/ml baseline free IgE in the patient's serum.
  • these methods are used to treat allergic rhinitis or allergic asthma.
  • the maintenance dose averages about 0.00075 to 0.0024 mg/kg/week, or about 0.00125 to 0.0024 mg/kg/week, or about 0.00175 to 0.0024 mg/kg/week, of IgE antagonist for every IU/ml baseline free IgE in the patient's serum.
  • the maintenance dose averages about 0.00075 to 0.0024 mg/kg/week, or about 0.00125 to 0.0024 mg/kg/week, or about 0.00175 to 0.0024 mg/kg/week, of IgE antagonist for every IU/ml baseline free IgE in the patient's serum.
  • the maintenance dose is at least about three fold lower, or at least about six fold lower, or at least about 12 fold lower, or at least about 25 fold lower, or at least about 50 fold lower, than the loading dose in units of mg/kg/week for every IU/ml baseline free IgE in the patient's serum.
  • the patient's serum free IgE response to the loading regimen can be determined by assaying the patient's serum free IgE according to the methods for baseline serum free IgE assay described above.
  • the patient's reactivity to skin prick allergen challenge can be determined according to the methods of Bousquet and Michel, "IN VIVO METHODS FOR STUDY OF ALLERGY: Skin tests, techniques and interpretation" Allergy Principles & Practice, Middleton et al., eds, pps. 573-594 (1992).
  • the maintenance dose averages about 0.00075 to 0.0024 mg/kg/week, or about 0.00125 to 0.0024 mg/kg/week, or about 0.00175 to 0.0024 mg/kg/week, of IgE antagonist for every IU/ml baseline free IgE in the patient's serum.
  • the maintenance dose is at least about three fold lower, or at least about six fold lower, or at least about 12 fold lower, or at least about 25 fold lower, or at least about 50 fold lower, than the loading dose in units of mg/kg/week for every IU/ml baseline free IgE in the patient's serum
  • the patient's reactivity to skin prick allergen challenge can be determined as described above
  • treatment efficacy is assessed by allergen-titrated skin prick tests conducted at various times before, during and after treatment with the study drug.
  • basophils are harvested from the patients at various times before, during and after treatment and assayed for FceRI expression as described in Example 1 above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthodes de traitement de maladies allergiques, par exemple de la rhinite allergique et de l'asthme allergique, avec des anticorps anti-IgE et autres antagonistes d'IgE.
PCT/US1997/003443 1996-03-12 1997-03-06 Methodes de traitement de maladies allergiques a l'aide d'ige WO1997033616A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU19875/97A AU726143B2 (en) 1996-03-12 1997-03-06 Methods for treatment of allergic diseases with IgE
JP53267597A JP2001505181A (ja) 1996-03-12 1997-03-06 アレルギー疾患の治療方法
IL12611397A IL126113A0 (en) 1996-03-12 1997-03-06 Methods for treatment of allergic diseases with ige
EP97908025A EP0904108A1 (fr) 1996-03-12 1997-03-06 METHODES DE TRAITEMENT DE MALADIES ALLERGIQUES A L'AIDE D'IgE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12
US08/614,220 1996-03-12

Publications (1)

Publication Number Publication Date
WO1997033616A1 true WO1997033616A1 (fr) 1997-09-18

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003443 WO1997033616A1 (fr) 1996-03-12 1997-03-06 Methodes de traitement de maladies allergiques a l'aide d'ige

Country Status (8)

Country Link
EP (1) EP0904108A1 (fr)
JP (1) JP2001505181A (fr)
AR (1) AR006202A1 (fr)
AU (1) AU726143B2 (fr)
CA (1) CA2246427A1 (fr)
IL (1) IL126113A0 (fr)
WO (1) WO1997033616A1 (fr)
ZA (1) ZA971607B (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039799A2 (fr) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Desensibilisation passive
WO2002089615A2 (fr) * 2001-05-03 2002-11-14 Novartis Ag Utilisation de composes organiques
US6780839B2 (en) 2000-07-04 2004-08-24 Pharmagene Laboratories Ltd. Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
US7060268B2 (en) 1995-07-27 2006-06-13 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US9180189B2 (en) 1995-07-27 2015-11-10 Genentech, Inc. Treating a mammal with a formulation comprising an antibody which binds IgE
CN114028569A (zh) * 2021-12-20 2022-02-11 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644A (zh) * 2021-12-24 2022-05-17 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
US20220235146A1 (en) * 2016-06-10 2022-07-28 UCB Biopharma SRL ANTI-IgE ANTIBODIES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
EP0550020A2 (fr) * 1991-12-24 1993-07-07 Snow Brand Milk Products Co., Ltd. Anticorps monoclonaux contre l'IgE humaine
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
EP0550020A2 (fr) * 1991-12-24 1993-07-07 Snow Brand Milk Products Co., Ltd. Anticorps monoclonaux contre l'IgE humaine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACQUEMIN MG ET AL: "Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes.", THERAPEUTIC IMMUNOLOGY, FEB 1995, 2 (1) P41-52, ENGLAND, XP002035433 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283273B2 (en) 1995-07-27 2016-03-15 Genentech, Inc. Protein formulation
US9180189B2 (en) 1995-07-27 2015-11-10 Genentech, Inc. Treating a mammal with a formulation comprising an antibody which binds IgE
US7060268B2 (en) 1995-07-27 2006-06-13 Genentech, Inc. Protein formulation
US7931898B2 (en) 1998-04-09 2011-04-26 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US8252907B2 (en) 1998-04-09 2012-08-28 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
WO2001039799A3 (fr) * 1999-12-06 2002-01-03 Panacea Pharm Llc Desensibilisation passive
WO2001039799A2 (fr) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Desensibilisation passive
US6780839B2 (en) 2000-07-04 2004-08-24 Pharmagene Laboratories Ltd. Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
WO2002089615A3 (fr) * 2001-05-03 2003-05-01 Novartis Ag Utilisation de composes organiques
WO2002089615A2 (fr) * 2001-05-03 2002-11-14 Novartis Ag Utilisation de composes organiques
US20220235146A1 (en) * 2016-06-10 2022-07-28 UCB Biopharma SRL ANTI-IgE ANTIBODIES
US12054559B2 (en) * 2016-06-10 2024-08-06 UCB Biopharma SRL Anti-IgE antibodies
CN114028569A (zh) * 2021-12-20 2022-02-11 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644A (zh) * 2021-12-24 2022-05-17 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Also Published As

Publication number Publication date
ZA971607B (en) 1998-08-25
AU726143B2 (en) 2000-11-02
IL126113A0 (en) 1999-05-09
AU1987597A (en) 1997-10-01
EP0904108A1 (fr) 1999-03-31
JP2001505181A (ja) 2001-04-17
CA2246427A1 (fr) 1997-09-18
AR006202A1 (es) 1999-08-11

Similar Documents

Publication Publication Date Title
EP0841946B1 (fr) Procedes de traitement de l'asthme allergique
Bel et al. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects
US5656273A (en) Method of treatment of parasitic infection using IgE antagonists
EP0611302B1 (fr) Recepteurs pour le traitement des troubles inflammatoires de phase tardive
MXPA98000760A (en) Methods for the treatment of asthma allergy
US20110311520A1 (en) Methods for treatment of allergic asthma
TAYLOR et al. Local nasal desensitization in allergic rhinitis
AU726143B2 (en) Methods for treatment of allergic diseases with IgE
EP1390067A1 (fr) Compositions permettant de traiter les troubles associes aux ige
KR100831118B1 (ko) 알레르기를 치료하기 위한 재조합 폴리클로날 항체 또는정제된 폴리클로날 항체
Cingi et al. Update on the medical treatment of allergic rhinitis
US20040141992A1 (en) Desensitizers
Lichtenstein The nasal late-phase response-an in vivo model
Concas et al. Omalizumab therapy in the management of severe allergic asthma
US20050101520A1 (en) CTLA4 compositions in the treatment of autism
Friedman Rhinology Abstracts
Paul-Eugene et al. PS12 Organ specific allergy (nasal, ocular, GI allergy)/Poster Session Discussion Thursday, 13: 30-16: 00, 16: 30-18: 00/Room 52a, 5th floor
Nadeau 40 Anti–Immunoglobulin E Therapy
Marti et al. 603 CONSULTATION DUE TO ADVERSE REACTIONS CAUSED BY LOCAL ANESTHETICS IN THE AREA OF BARCELONA
SWEENEY et al. Pulmonary Delivery of Anti-IgE
JP2003504412A (ja) ＩｇＥをダウンレギュレーションするための小ペプチドおよび方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997908025

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2246427

Country of ref document: CA

Ref country code: CA

Ref document number: 2246427

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 532675

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997908025

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997908025

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载